Contrasting Qualigen Therapeutics (NASDAQ:QLGN) and Soleno Therapeutics (NASDAQ:SLNO)

Qualigen Therapeutics (NASDAQ:QLGN) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Qualigen Therapeutics and Soleno Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Soleno Therapeutics	1	1	12	1	2.87

Soleno Therapeutics has a consensus target price of $104.54, suggesting a potential upside of 218.71%. Given Soleno Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Qualigen Therapeutics.

Volatility & Risk

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -3.16, suggesting that its share price is 416% less volatile than the S&P 500.

Earnings and Valuation

This table compares Qualigen Therapeutics and Soleno Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26 million	($7.50)	-0.19
Soleno Therapeutics	$190.40 million	8.89	$20.89 million	$0.23	142.61

Soleno Therapeutics has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Qualigen Therapeutics and Soleno Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Soleno Therapeutics	N/A	5.90%	4.61%

Institutional & Insider Ownership

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Soleno Therapeutics beats Qualigen Therapeutics on 12 of the 13 factors compared between the two stocks.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.